{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    55,
    56,
    58,
    59,
    62,
    68,
    71,
    75,
    76,
    77
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_3",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose"
      },
      {
        "id": "anchor_1",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "day of randomization"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_4",
        "definition": "transplant",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "transplant"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "interval": "PT6H",
        "sourceText": "every 6 hours"
      },
      {
        "id": "rep_interval_2",
        "type": "Interval",
        "sourceText": "bid"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P3D",
        "sourceText": "Up to 3 cycles"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P5D",
        "endOffset": "-P3D",
        "sourceText": "day -5 to day -3"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P5D",
        "endOffset": "-P3D",
        "sourceText": "day -5 through day -3"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P4D",
        "sourceText": "days 1-4"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "observation period"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "sourceText": "Follow-up Period"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "7 days after"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "5 days after"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "48 hours before"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P63D",
        "interval": "P21D",
        "minObservations": 2,
        "exitCondition": "Subjects responding to second-line combination chemotherapy after 2 or 3 cycles (PR or CR) should proceed to high-dose therapy (HDT) and autologous stem cell transplant (ASCT).",
        "sourceText": "Up to 3 cycles (6 to 9 weeks) of combination chemotherapy will be administered every 2 to 3 weeks."
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "-P5D",
        "endOffset": "-P3D",
        "interval": "P1D",
        "minObservations": 3,
        "exitCondition": "Completion of 3-day regimen",
        "sourceText": "receive a 3 day conditioning chemotherapy regimen consisting of fludarabine 30 mg/m2/day and cyclophosphamide 500 mg/m2/day (day -5 to day -3)"
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P7D",
        "interval": "P1D",
        "minObservations": 7,
        "exitCondition": "Minimum 7 days unless otherwise required by country regulatory agencies",
        "sourceText": "Subjects will be under an observation period for at least 7 days after axicabtagene ciloleucel infusion to monitor for and manage any adverse events"
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P15Y",
        "interval": "null",
        "minObservations": 1,
        "exitCondition": "15-year follow-up completion",
        "sourceText": "subjects who received at least one dose of axicabtagene ciloleucel as protocol therapy will complete the remainder of the 15-year follow-up assessments"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "RANDOMIZATION",
          "TREATMENT",
          "DISEASE_ASSESSMENT",
          "FOLLOW_UP",
          "LONG_TERM_FOLLOW_UP"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study",
          "Screening",
          "Randomization",
          "Day 50 Disease Assessment",
          "Day 1",
          "Day 150 Disease Assessment"
        ],
        "sourceText": "[{'condition': 'Randomized to Axicabtagene Ciloleucel Arm', 'path': ['CONDITIONING_CHEMOTHERAPY', 'AXI_CEL_INFUSION_DAY_0', 'POST_INFUSION_MONITORING']}, {'condition': 'Randomized to Standard of Care (SOC) Arm', 'path': ['SALVAGE_COMBINATION_CHEMOTHERAPY', 'RESPONSE_ASSESSMENT', 'HIGH_DOSE_THERAPY_AND_ASCT_IF_RESPONDER']}, {'condition': 'Non-responder to SOC chemotherapy', 'path': ['OFF_PROTOCOL_TREATMENT', 'SURVIVAL_FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Draw",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "WINDOW signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Ct Scan",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 8"
      },
      {
        "activityId": "Diary",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "Assessment of age-adjusted International Prognostic Index (IPI) and stratification factors occurs once at the time of screening."
      },
      {
        "activityId": "Randomization",
        "executionType": "Single",
        "rationale": "Subjects are randomized in a 1:1 ratio once to either axicabtagene ciloleucel or SOC."
      },
      {
        "activityId": "Standard of Care (SOC) Salvage Chemotherapy",
        "executionType": "Single",
        "rationale": "SOC consists of a protocol-defined platinum-based salvage combination chemotherapy regimen administered in cycles."
      },
      {
        "activityId": "High-dose therapy (HDT) and autologous stem cell transplant (ASCT)",
        "executionType": "Single",
        "rationale": "Conditional workflow where subjects only proceed to HDT and ASCT if they achieve a partial response (PR) or complete response (CR) to second-line chemotherapy."
      },
      {
        "activityId": "Data Safety Monitoring Board (DSMB) Review",
        "executionType": "Single",
        "rationale": "The DSMB meets continuously every 6 months after the first subject is randomized to review safety data over the duration of the trial."
      },
      {
        "activityId": "Event-free Survival (EFS) Monitoring",
        "executionType": "Single",
        "rationale": "Continuous monitoring from the time of randomization until the earliest date of disease progression, new therapy, or death."
      },
      {
        "activityId": "Patient Reported Outcomes (PROs) and Quality of Life (QoL)",
        "executionType": "Single",
        "rationale": "Evaluations of PROs and QoL are typically scheduled at specific repeated intervals/visits throughout the study period."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "frequency_daily",
        "text": "a. Physical Exam: Subjects with new-onset symptoms related to CRS should undergo physical examination at least daily until symptoms resolve to baseline.",
        "footnoteId": "fn_1",
        "structuredCondition": "if(symptoms.CRS == 'new-onset') { frequency.min(P1D) until(symptoms.CRS == 'baseline') }",
        "appliesToActivityIds": [
          "Physical Exam"
        ],
        "sourceText": "a. Physical Exam: Subjects with new-onset symptoms related to CRS should undergo physical examinatio"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Neurologic assessment: A neurological assessment should be done prior to axicabtagene ciloleucel infusion on treatment day 0, then on treatment day 1 and every other day during the minimum 7-day observation period.",
        "footnoteId": "fn_2",
        "structuredCondition": "timing.before(axicabtagene_ciloleucel_infusion, D0); timing.at(D1); timing.frequency(P2D) until(D7)",
        "appliesToActivityIds": [
          "Neurologic assessment"
        ],
        "sourceText": "b. Neurologic assessment: A neurological assessment should be done prior to axicabtagene ciloleucel "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "c. Echo: Performed following the subjects last chemotherapy treatment and within 28 days prior to signing the consent may be used for confirmation of eligibility",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.after(last_chemotherapy) && timing.before(consent_signing, P28D)",
        "appliesToActivityIds": [
          "Echo"
        ],
        "sourceText": "c. Echo: Performed following the subjects last chemotherapy treatment and within 28 days prior to si"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "d. PET-CT disease assessment: PET-CT should be performed as close to randomization as possible and within 28 days prior to randomization.",
        "footnoteId": "fn_4",
        "structuredCondition": "timing.before(randomization, P28D) && timing.minimize_delta(randomization)",
        "appliesToActivityIds": [
          "PET-CT disease assessment"
        ],
        "sourceText": "d. PET-CT disease assessment: PET-CT should be performed as close to randomization as possible and w"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. Archived tumor sample: Archived tumor samples will be submitted to central laboratory for evaluation of CD19 expression and prognostic variables.",
        "footnoteId": "fn_5",
        "structuredCondition": "procedure.submit_to(central_laboratory) for(CD19_expression, prognostic_variables)",
        "appliesToActivityIds": [
          "Archived tumor sample"
        ],
        "sourceText": "e. Archived tumor sample: Archived tumor samples will be submitted to central laboratory for evaluat"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_before",
        "text": "f. Blood draw for anti-axicabtagene ciloleucel antibodies: Baseline antibody samples to be collected prior to start of leukapheresis.",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.before(leukapheresis, baseline)",
        "appliesToActivityIds": [
          "Blood draw for anti-axicabtagene ciloleucel antibodies"
        ],
        "sourceText": "f. Blood draw for anti-axicabtagene ciloleucel antibodies: Baseline antibody samples to be collected"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. Lumbar Puncture: Subjects with new onset Grade >= 2 neurologic symptoms post axicabtagene ciloleucel infusion will have lumbar puncture performed.",
        "footnoteId": "fn_7",
        "structuredCondition": "if(symptoms.neurologic >= Grade_2 && timing.after(axicabtagene_ciloleucel_infusion)) { procedure.perform() }",
        "appliesToActivityIds": [
          "Lumbar Puncture"
        ],
        "sourceText": "g. Lumbar Puncture: Subjects with new onset Grade >= 2 neurologic symptoms post axicabtagene ciloleu"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. Blood draws for PBMCs, cytokines, and additional analysis per Section 7.11.2.",
        "footnoteId": "fn_8",
        "structuredCondition": "procedure.reference(Section_7.11.2)",
        "appliesToActivityIds": [
          "Blood draws for PBMCs",
          "cytokines",
          "additional analysis"
        ],
        "sourceText": "h. Blood draws for PBMCs, cytokines, and additional analysis per Section 7.11.2."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_before",
        "text": "i. EORTC QLQ-C30/EQ-5D-5L/WPAI: To be completed by the subject before any procedures are performed-excluding blood draws.",
        "footnoteId": "fn_9",
        "structuredCondition": "timing.before(all_procedures) except(blood_draws)",
        "appliesToActivityIds": [
          "EORTC QLQ-C30",
          "EQ-5D-5L",
          "WPAI"
        ],
        "sourceText": "i. EORTC QLQ-C30/EQ-5D-5L/WPAI: To be completed by the subject before any procedures are performed-e"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j. Adverse Events: The investigator is responsible for reporting all adverse events observed by the investigator or reported by the subject.",
        "footnoteId": "fn_10",
        "structuredCondition": "responsibility.investigator(report_all_AEs)",
        "appliesToActivityIds": [
          "Adverse Events"
        ],
        "sourceText": "j. Adverse Events: The investigator is responsible for reporting all adverse events observed by the "
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "k. Concomitant medications should be recorded from the date of the informed consent through the Day 150 post-randomization visit.",
        "footnoteId": "fn_11",
        "sourceText": "k. Concomitant medications should be recorded from the date of the informed consent through the Day "
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. For European Union (EU) sites, viral serologic tests (eg, HIV, Hep B, Hep C) will be carried out per institution guidelines and EU regulations.",
        "footnoteId": "fn_12",
        "sourceText": "l. For European Union (EU) sites, viral serologic tests (eg, HIV, Hep B, Hep C) will be carried out "
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_after",
        "text": "m. Subjects will be monitored daily through day 7 after treatment with axicabtagene ciloleucel unless otherwise required by country regulatory agencies.",
        "footnoteId": "fn_13",
        "sourceText": "m. Subjects will be monitored daily through day 7 after treatment with axicabtagene ciloleucel unles"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Event-free Survival (EFS)",
        "endpointType": "Primary",
        "inputs": [
          "randomization_date",
          "disease_progression_date",
          "new_lymphoma_therapy_start_date",
          "death_date",
          "analysis_cutoff_date"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until_event_or_cutoff"
        },
        "algorithm": "min(disease_progression_date, new_lymphoma_therapy_start_date, death_date) - randomization_date",
        "successCriteria": "Prolonged EFS compared to SOC (hypothesized 50% improvement)",
        "sourceText": "EFS is defined as the time from randomization to the earliest date of disease progression per the Lugano Classification {Cheson 2014}, commencement of new lymphoma therapy, or death from any cause."
      },
      {
        "id": "ep_2",
        "name": "Objective Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "subjects_with_response",
          "total_randomized_subjects"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "post_baseline"
        },
        "algorithm": "subjects_with_response / total_randomized_subjects",
        "successCriteria": "Statistically significant improvement compared to SOC",
        "sourceText": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on objective response rate (ORR), as detennined by blinded centrnl review"
      },
      {
        "id": "ep_3",
        "name": "Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "randomization_date",
          "death_date",
          "analysis_cutoff_date"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "up_to_5_years"
        },
        "algorithm": "death_date - randomization_date",
        "successCriteria": "Statistically significant improvement compared to SOC",
        "sourceText": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on overall survival (OS)"
      },
      {
        "id": "ep_4",
        "name": "Progression-free Survival (PFS)",
        "endpointType": "Secondary",
        "inputs": [
          "randomization_date",
          "disease_progression_date",
          "death_date"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until_progression_or_death"
        },
        "algorithm": "min(disease_progression_date, death_date) - randomization_date",
        "successCriteria": "Improvement compared to SOC",
        "sourceText": "To evaluate the effect of axicabtagene ciloleucel compared to SOC on progression-free smvival (PFS)"
      },
      {
        "id": "ep_5",
        "name": "Quality of Life Change (EORTC QLQ-C30)",
        "endpointType": "Secondary",
        "inputs": [
          "screening_score",
          "post_baseline_score"
        ],
        "timeWindow": {
          "reference": "screening",
          "duration": "post_baseline"
        },
        "algorithm": "post_baseline_score - screening_score",
        "successCriteria": "Improvement or maintenance of global health status/physical functioning",
        "sourceText": "Changes from screening to post baseline in the global health status QoL scale and the physical functioning domain of the European Organisation for Research and Treatment of Cancer Quality of Life Ques"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Event-free Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Progression",
          "Date of Death",
          "Date of New Anti-lymphoma Therapy"
        ],
        "derivationRule": "Time from randomization to the date of first documentation of progression, death from any cause, or commencement of new anti-lymphoma therapy.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 0",
        "analysisWindow": "Study duration until event or censoring",
        "imputationRule": "Censoring rules per protocol for subjects without events",
        "unit": "Months"
      },
      {
        "id": "dv_2",
        "name": "ORR",
        "variableType": "Categorical",
        "sourceVariables": [
          "Best Objective Response"
        ],
        "derivationRule": "Proportion of subjects who achieve a best response of CR or PR.",
        "baselineDefinition": "Pre-treatment disease assessment",
        "baselineVisit": "Screening",
        "analysisWindow": "Post-baseline assessments",
        "imputationRule": "Non-responders for missing data",
        "unit": "Percentage"
      },
      {
        "id": "dv_3",
        "name": "OS",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Death"
        ],
        "derivationRule": "Time from randomization to the date of death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 0",
        "analysisWindow": "Long-term follow-up",
        "imputationRule": "Censored at date last known alive",
        "unit": "Months"
      },
      {
        "id": "dv_4",
        "name": "Progression-free Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Progression",
          "Date of Death"
        ],
        "derivationRule": "Time from randomization to the date of first documentation of progression or death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 0",
        "analysisWindow": "Study duration until event or censoring",
        "imputationRule": "Censoring rules per protocol",
        "unit": "Months"
      },
      {
        "id": "dv_5",
        "name": "Duration of Response",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of First Response (CR or PR)",
          "Date of Progression",
          "Date of Death"
        ],
        "derivationRule": "Time from the first objective response to the date of progression or death.",
        "baselineDefinition": "Date of first documented CR or PR",
        "baselineVisit": "Post-baseline",
        "analysisWindow": "From response until event",
        "imputationRule": "Censored at date of last evaluable disease assessment",
        "unit": "Months"
      },
      {
        "id": "dv_6",
        "name": "Time to Next Therapy",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of New Anti-lymphoma Therapy"
        ],
        "derivationRule": "Time from randomization to the start date of the first new anti-lymphoma therapy.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 0",
        "analysisWindow": "Study duration",
        "imputationRule": "Censored at last contact or death",
        "unit": "Months"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Randomization",
        "Treatment",
        "Disease Assessment",
        "Follow Up",
        "Long Term Follow Up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Randomization",
          "trigger": "Progress to Randomization"
        },
        {
          "fromState": "Randomization",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Disease Assessment",
          "trigger": "Progress to Disease Assessment"
        },
        {
          "fromState": "Disease Assessment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Follow Up",
          "toState": "Long Term Follow Up",
          "trigger": "Progress to Long Term Follow Up"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Randomization": "RANDOMIZATION",
        "Treatment": "TREATMENT",
        "Disease Assessment": "DISEASE_ASSESSMENT",
        "Follow Up": "FOLLOW_UP",
        "Long Term Follow Up": "LONG_TERM_FOLLOW_UP",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "Axicabtagene ciloleucel",
        "frequency": "Single",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 2000000.0,
            "unit": "anti-CD19 CAR T cells/kg",
            "description": "Target dose"
          }
        ],
        "durationDescription": "One-time dose"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Fludarabine",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 30.0,
            "unit": "mg/m2/day",
            "description": "Conditioning chemotherapy"
          }
        ],
        "durationDescription": "3 days"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Cyclophosphamide",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 500.0,
            "unit": "mg/m2/day",
            "description": "Conditioning chemotherapy"
          }
        ],
        "durationDescription": "3 days"
      },
      {
        "id": "dosing_llm_4",
        "treatmentName": "Standard of Care (SOC) - Platinum-based salvage combination chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP)",
        "frequency": "Q3W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "2 to 3 cycles (6 to 9 weeks)",
        "doseModifications": [
          "Subjects responding to second-line combination chemotherapy after 2 or 3 cycles (PR or CR) should proceed to high-dose therapy (HDT) and autologous stem cell transplant (ASCT)."
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_2",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "(0 to 1 vs 2 to 3) as assessed at the time of screening. For subjects randomized to the control arm of the study, SOC will consist of a protocol-defined, platinum-based salvage combination chemotherap"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Conditioning Chemotherapy Day -5",
        "targetDay": -5,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Conditioning"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Conditioning Chemotherapy Day -4",
        "targetDay": -4,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Conditioning"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Conditioning Chemotherapy Day -3",
        "targetDay": -3,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "epoch": "Conditioning"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Rest Day -2",
        "targetDay": -2,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Pre-Infusion"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Rest Day -1",
        "targetDay": -1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Pre-Infusion"
      },
      {
        "id": "visit_3",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "response [PR] or complete response [CR]) should proceed to high-dose therapy (HDT) and autologous stem cell transplant (ASCT). An independent Data Safety Monitoring Board (DSMB) will meet every"
      },
      {
        "id": "visit_5",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "marrow biopsy; disease staging, including a baseline PET-CT scan; and blood draws for lactate dehydrogenase levels, complete blood count (CBC), and blood chemistries. Subjects will also undergo baseli"
      },
      {
        "id": "visit_10",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "MSGV1 Murine stem cell virus-based vector NCI"
      },
      {
        "id": "visit_11",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "The end of study is defined as when the last remaining subject completes their last visit on this study and transitions to a separate LTFU study (Section 3.5.3), or, when the last remaining subject, w"
      },
      {
        "id": "visit_12",
        "visitName": "Month 12",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "Month 12, or until a change in lymphoma therapy, or disease progression, whichever occurs first. Targeted concomitant therapies include gammaglobulin, immunosuppressive drugs, anti-infective drugs, an"
      },
      {
        "id": "visit_16",
        "visitName": "Month 9",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "through Month 9 or until change in lymphoma therapy or disease progression, whichever comes first. If subject’s disease has not progressed by Month 9, disease assessments can be evaluated per CT scans"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Leukapheresis",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Pre-Treatment"
      },
      {
        "id": "visit_llm_10",
        "visitName": "SOC Cycle 1",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 1,
        "epoch": "SOC Treatment"
      },
      {
        "id": "visit_llm_11",
        "visitName": "SOC Cycle 2",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 3,
        "epoch": "SOC Treatment"
      },
      {
        "id": "visit_llm_12",
        "visitName": "SOC Cycle 3",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 12,
        "targetWeek": 6,
        "epoch": "SOC Treatment"
      },
      {
        "id": "visit_llm_13",
        "visitName": "Long-term Follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 13,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_1",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "1:1 ratio to receive axicabtagene ciloleucel or SOC. Randomization will be stratified by response to first-line therapy (primary refractory, vs relapse ≤ 6 months of first-line therapy vs relapse > 6 "
      },
      {
        "id": "visit_13",
        "visitName": "Day 2",
        "targetDay": 2,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "sourceText": "Ifosfamide 5 g/m2 24h-CI on day 2 with mesna • Carboplatin area under the curve (AUC) 5 on day 2, maximum dose 800 mg"
      },
      {
        "id": "visit_15",
        "visitName": "Day 5",
        "targetDay": 5,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "sourceText": "Cytarabine 2 g/m2 on day 5"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Observation Period (Post-Infusion)",
        "targetDay": 7,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 1,
        "epoch": "Post-Treatment"
      },
      {
        "id": "visit_7",
        "visitName": "Day 50",
        "targetDay": 50,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "sourceText": "Day 50 (from randomization) Disease Assessmentb Day 150 (from randomization) Disease Assessmentb Treatment Period: Standard of Care Therapy Treatment Arm"
      },
      {
        "id": "visit_9",
        "visitName": "Day 100",
        "targetDay": 100,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 23,
        "sourceText": "Day 100 (from randomization) Disease Assessmentb a Bridging therapy: At the discretion of the investigator, corticosteroid bridging therapy may be considered for subjects with high disease"
      },
      {
        "id": "visit_8",
        "visitName": "Day 150",
        "targetDay": 150,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 24,
        "sourceText": "Day 150 (from randomization) Disease Assessmentb Treatment Period: Standard of Care Therapy Treatment Arm Subjects randomized to the SOC arm will receive a second-line"
      },
      {
        "id": "visit_6",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 25,
        "sourceText": "Long-term Follow-up (LTFU) study. For a subject who completes the entire protocol from the date of informed consent through the completion of the long-term follow-up period, the"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Age",
          "categories": [
            "<5 years",
            "≥5 years"
          ],
          "isBlocking": false,
          "sourceText": "response to first-line therapy (primary refractory, vs relapse \n≤ 6 months of first-line therapy vs relapse > 6 and ≤ 12 months of  first-line \ntherapy) and second-line age-adjusted international prog"
        },
        {
          "id": "strat_llm_1",
          "name": "Response to first-line therapy",
          "categories": [
            "primary refractory",
            "relapse ≤ 6 months of first-line therapy",
            "relapse > 6 and ≤ 12 months of first-line therapy"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Second-line age-adjusted International Prognostic Index (IPI)",
          "categories": [
            "0 to 1",
            "2 to 3"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Axicabtagene ciloleucel; KTE-C19\nKite Pharma, Inc.\nClinical Protocol: KTE-C19-107 (ZUMA-7)\nAmendment 6\nCONFIDENTIAL\nPage 2\n14 April 2023\nPROTOCOL SYNOPSIS\nTitle:\nA Phase 3, Randomized, Open-Label Stud"
    }
  }
}